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Anthrax lethal toxin (LeTx) is a virulence factor secreted by
Bacillus anthracis and has direct cytotoxic effects on most cells
once released into the cytoplasm. The cytoplasmic delivery of
the proteolytically active component of LeTx, lethal factor (LF),
is carried out by the transporter component, protective antigen,
which interacts with either of two known surface receptors
known as anthrax toxin receptor (ANTXR) 1 and 2. We found
that the cytoplasmic delivery of LF byANTXR2wasmediated by
cathepsin B (CTSB) and required lysosomal fusion with LeTx-
containing endosomes. Also, binding of protective antigen to
ANXTR1 or -2 triggered autophagy, which facilitated the cyto-
plasmic delivery of ANTXR2-associated LF. We found that
whereas cells treated with the membrane-permeable CTSB
inhibitor CA074-Me- or CTSB-deficient cells had no defect in
fusion of LC3-containing autophagic vacuoles with lysosomes,
autophagic flux was significantly delayed. These results sug-
gested that the ANTXR2-mediated cytoplasmic delivery of LF
was enhanced by CTSB-dependent autophagic flux.
Anthrax lethal toxin (LeTx)2 and edema toxin are two key
virulence factors secreted by Bacillus anthracis, the causative
agent of anthrax (1, 2). LeTx and edema toxin are composed of
lethal factor (LF) or edema factor (EF), respectively, and protec-
tive antigen (PA), which functions as a cytoplasmic transporter
of LF or EF. These toxins are main contributors to the clinical
manifestations of anthrax and are cytotoxic to host cells once
delivered into the cytoplasm. EF is an adenylate cyclase that
raises cAMP levels in cells (3). LF is a metalloproteinase that
targets the N-terminal end of the mitogen-activated protein
kinase kinase 1–7 (MEK1–7) (except MEK5) (4–6) and in cer-
tain mouse cells induces pyronecrosis by activating NACHT-
leucine-rich repeat and pyrin domain-containing protein 1b
(NALP1b) (7).
Incorporation of LF or EF into the cytoplasm is initiated by
the binding of PA to the host cell surface through interacting
with either of two known receptors: anthrax receptor 1
(ANTXR1, also known as the tumor endothelial marker 8) (8)
and ANTXR2 (also known as the capillary morphogenesis
gene-2) (9). Both ANTXR1 and -2 are widely distributed in
human tissues and share molecular and biochemical similari-
ties in their extracellular PA interacting domains known as von
Willebrand factor A or integrin-like inserted (I) domain (10),
post-translational modifications such as palmitoylation and
ubiquitination of cytoplasmic domains (11), and associations
with the co-receptor lipoprotein receptor-related 6 molecule
(12, 13). ANTXR1 and -2 are also distinct in that ANTXR1 is
highly expressed in tumor endothelial and cancer cells, and
ANTXR2 has a higher binding affinity to PA and requires
a lower pH to form a transmembrane pore than ANTXR1
(10, 14).
After binding PA to either ANTXR, a furin-like surface pro-
tease then cleaves PA at the N-terminal end to release a 20-kDa
soluble fragment, yielding membrane-associated 63-kDa PA
(PA63) that forms a ring-shape heptameric oligomerization or
prepore and binds LF or EF followed by a lipid raft and clathrin-
mediated endocytosis (15, 16). The PA63 heptamers then
undergo a pH-dependent conformational change and form
pores as the carrier endosomes mature into early endosomes,
endosomal carrier vesicles (or multivesicular bodies), and late
endosomes. The dissociation and release of LF or EF from PA
through the PA63 poreswas shown to occur in themembrane of
intralumenal vesicles rather than in that of early endosomes
whereby LF or EF are transferred to the lumen of the carrier
vesicle before being delivered into the cytoplasm through a
back fusion process (17, 18). The differences in binding affini-
ties and acidity requirements for pore formation between
ANTXR1 and -2 suggest that ANXTR1 and -2 utilize separate
routes of LF or EF release into the cytoplasm (14). However,
details in the delivery of LF or EF by ANTXR1 and -2 and the
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Supplemental Material can be found at:
mechanisms of the intralumenal vesicle back fusion with the
limiting membrane are largely unknown.
Cathepsin B (CTSB) is a lysosomal cysteine protease primar-
ily involved in the degradation or processing of lysosomal pro-
teins (19). In certain conditions CTSB has been shown to be
involved in additional cellular processes including cell invasion
(20), vesicle trafficking (21), inflammasome formation (22–24),
and cell death (25). Because CTSB was shown to be involved in
NALP3 inflammasome and caspase-1 activation (23, 24, 26),
which shares signaling mechanisms with NALP1b pathways,
we have examined the role of CTSB in LeTx cytotoxicity. How-
ever, unexpectedly, we found an unknown function of CTSB in
autophagy vesicle trafficking and the cytoplasmic delivery
LeTx. This study suggested that LF associated with ANTXR2,
but not ANTXR1, was released into the cytoplasm through
an endocytic trafficking route involving lysosomal fusion
and CTSB-dependent autophagy flux.
EXPERIMENTAL PROCEDURES
Materials and Reagents—Cathepsin B inhibitor IV (CA074-
Me) was purchased from Peptide Institute. MG132, cathepsin
K inhibitor, cathepsin G inhibitor, and vinblastine were pur-
chased from Calbiochem. 3-Methyladenine (3-MA) was pur-
chased from Sigma. LF and PA were prepared in the labora-
tory as previously described (27, 28), and inactive Lethal
Factor (mLF) was purchased from List Biological Laborato-
ries. Antibodies for LC3, phospho-ERK, and p38 mitogen-
activated protein kinase were obtained from Cell Signaling
Technologies (Pickering, ON). Antibody raised against the N
terminus of MEK1 was obtained from QED Bioscience Inc.
Antibodies toward lethal factor and protective antigen were
a gift from Dr. Stephen H. Leppla (National Institutes of
Health, Bethesda, MD). Antibodies for Rab-7, EEA1, actin,
and SYBL1 were obtained from Abcam (Cambridge, MA).
Cathepsin B antibody was purchased from Calbiochem.
GFP-LC3 plasmid was provided by Dr. T. Yoshimori
(National Institute for Basic Biology, Okazaki, Japan).
pCDNA-ANTXR1-SV1-HA and pCDNA-ANTXR2-HA
plasmids were provided by Dr. Jeremy Mogridge (University
of Toronto).
Cell Culture—RAW264.7 murine macrophages, HEK293
cells, and the lysosome-associated membrane protein 1
(LAMP-1)/LAMP-2 double-deficient or wild type mouse
embryonic fibroblasts cell lines were cultured in DMEM
medium containing 10% heated-inactivated fetal bovine
serum (Sigma), 10 mM MEM nonessential amino acids solu-
tion, 100 units/ml penicillin G sodium, 100 g/ml strepto-
mycin sulfate, and 1 mM sodium pyruvate. DMEM medium
containing 8% heat-inactivated fetal bovine serum was used
for RAW264.7 murine macrophages. Cells were grown at
37°C in a humidified atmosphere containing 5% CO2.
LAMP-1/LAMP-2 double-deficient and wild type murine
embryonic fibroblast (MEF) cell lines were obtained from
Dr. Paul Saftig (University of Kiel). Mouse bone marrow-
derived macrophages from CTSB-deficient (Ctsb/) or
control strain C57 BL/6 (Ctsb/) mice were cultured in
RPMI 1640 medium containing macrophage colony-stimu-
lating factor (21). The human monocytic cell line THP-1 was
cultured in RPMI 1640 medium containing 10% heat-inacti-
vated fetal bovine serum (Sigma), 10 mM MEM nonessential
amino acids solution, 100 units/ml penicillin G sodium, 100
g/ml streptomycin sulfate, and 1 mM sodium pyruvate.
Cells were grown at 37 °C in a humidified atmosphere con-
taining 5% CO2. CHOR1.1 and CHOR1.1-ANTXR1-SV1 sta-
bly transfected cell lines were kind gifts from Dr. Jeremy
Mogridge (University of Toronto) and were maintained in
DMEM/F-12 (1:1) media. Cells were grown at 37 °C in a
humidified atmosphere containing 5% CO2.
Measurement of Cell Viability—RAW264.7 macrophages
were cultured for the indicated times in the presence or absence
of LeTx in 96-well plates, and MTT was added at a final con-
centration of 1 mg/ml. After incubating at 37 °C for an addi-
tional 2 h, culture media was carefully aspirated, and 100 l of
dimethyl sulfoxide (DMSO) was added to dissolve crystals.
Optical densities of the wells were analyzed using an automatic
enzyme-linked immunosorbent assay plate reader (Bio-Rad) at
a wavelength of 590 nm. The ratio of cell death was determined
based on the optical density of the wells compared with those
from nontreated cells as no cell death.
Small Interfering RNA—Human vesicle-associated mem-
brane protein 7 (VAMP7; SYBL1) and ANTXR1- and
ANTXR2-specific small interference RNAs (siRNAs) were pur-
chased from Thermo Scientific (Dharmacon, for SYBL1; ON-
TARGET plus SMART pool L-020864-00-0005, for ANTXR1;
ON-TARGET plus SMART pool L-010679-00-0005, for
ANTXR2; ON-TARGET plus SMART pool ID# L-015215-01-
0005), and the siRNA negative control was purchased from
Ambion. Transfections of HEK293 cells or THP-1 cells with
siRNAs were performed using Lipofectamine 2000 (Invitro-
gen). At 42 h post-transfection some of cells were harvested
for validation of siRNA using reverse transcription-PCR or
Western blots, and others were treated with LeTx for traf-
ficking analysis. Total RNA was isolated using Trizol
(Invitrogen), and cDNA was synthesized using Moloney
murine leukemia virus reverse transcriptase (New England
Biolabs) according to the manufacturer’s instructions.
Oligonucleotide primers for PCR were: for hANTXR1, 5-
ATGCCTTGTGGGTCCTACTG-3 (forward) and 5-GAGGT-
GTGGTAGGCGTTGTT-3 (reverse); for hANTXR2, 5-AAG-
GACGGGAGGATTCTGTT-3 (forward) and 5-CAGC-
CAGCCAGTGACATAAA-3 (reverse).
Total Cell Lysate Preparation and Immunoblot Analysis—
Total cell lysate preparation and immunoblotting procedures
were performed as previously described (29). Briefly, cells were
lysed in ice-cold lysis buffer (20 mMMOPS, 2 mM EGTA, 5 mM
EDTA, 1 mM Na3VO4, 40 mM -glycerophosphate, 30 mM
sodium fluoride, 20 mM sodium pyrophosphate, and 1% Triton
X, pH 7.2) containing a protease inhibitor mixture (Roche
Applied Science). The cell lysates were incubated on ice for 10
min and centrifuged at 12,500 rpm for 15 min at 4 °C. The
supernatants were separated by SDS-polyacrylamide gels fol-
lowed by transfer onto nitrocellulose membranes (Bio-Rad).
Themembraneswere blockedwith 5% (w/v) skimmilk for 1 h at
room temperature for and then incubated overnight at room
temperature with the primary antibody. The membranes were
washed, incubatedwith secondary antibody for 1 h (Pierce), and
Cathepsin B in ANTXR2-mediated Toxin Delivery
JANUARY 15, 2010 • VOLUME 285 • NUMBER 3 JOURNAL OF BIOLOGICAL CHEMISTRY 2121










developed using an enhanced chemiluminescence detection
system (ECL) (Pierce).
Subcellular Fractionation—Endosomal fractionations were
prepared by sucrose step gradient (30) after preparing subcel-
lular fractions using a lysosome isolation kit (Sigma). Detailed
procedures followed the manufacturer’s instructions, and all
steps were carried out at 4 °C or on ice. Briefly, cells were
washed with PBS and resuspended with 1 homogenization
buffer containing protease inhibitor mixture and homogenized
gently to limit damage to endosomes. The post-nuclear super-
natant (PNS) was prepared by centrifugation for 10 min at
1,000  g, and PNS was centrifuged at 20,000  g for 20 min.
The supernatant was collected as the cytosolic fraction for
Western blot, and the pellet was resuspended with 1 homog-
enization buffer. Optiprep density gradient solutions were pre-
pared according to the manufacturer’s instructions for loading
on the gradient. The gradient was centrifuged for 10 h at 35,000
rpm in a SW41 swinging bucket rotor (Beckman Instruments),
and gradient fractions were collected and analyzed by
immunoblots.
Immunofluorescence Staining and Lethal Toxin Trafficking
Analysis—HEK293 cells were plated on coverslips and incu-
bated in the presence or absence of CA074-Me for 1 h at 37 °C
in 5%CO2.Cellswere then treatedwith the LeTx (250ng/ml PA
and LF) for 1 h and washed twice with normal growth media to
remove unbound toxins, and cells were further incubated at
37 °C for 1 h in 5% CO2. Cells were fixed in 4% formaldehyde
and blocked with 10% normal goat serum. Endogenous cathep-
sin B or endocytosed PA or LF were detected by immunofluo-
rescence staining using the Vector Laboratories system and
observed through a Bio-Rad Radiance 2000 two-photon fluo-
rescence confocal microscope. For colocalization of GFP-LC3
and PA or LF, RAW264.7 cells were electroporated with the
GFP-LC3 plasmid. At 16 h post-transfection, cells were treated
with LeTx and immunostained as above. Immunofluorescence
images were obtained and analyzed using a Zeiss LSM510
META confocal microscope and ZEN software.
Electron Microscopy—Cells were grown on 100-cm dishes
and incubated in the presence or absence of LeTx for 1 h at
37 °C in 5% CO2. Cells were washed with PBS twice and fixed
with 2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer for
2 h at room temperature. Grids with specimen were prepared
by the Transmission Electron Microscope Facility at The Uni-
versity of Western Ontario (Canada), and micrographs were
taken with a transmission electron microscope. Briefly, after
fixing with 2.5% glutaraldehyde, Cells were washed with 0.1 M
cacodylate buffer 3 times, and cells were further fixed with 1%
osmium tetroxide in 0.1 M cacodylate buffer for 1 h and then
rinsed with 0.1 M cacodylate buffer. Cells were enrobed in 5%
Noble Agar and washed with distilled water 5 times, further
fixingwith 2% uranyl acetate for 2 h, followed by dehydration in
50% (15 min), 70% (16 h), 85% (15 min), 95% (15 min), and 2
changes of 100% ethanol each 15 min. They were then cleared
by 2 changes of propylene oxide, each 15 min, and infiltrated
with epon resin:propylene oxide (1:1) for 3 h, epon resin:pro-
pylene oxide (3:1) for 16 h, and 2 changes with pure epon resin
for total 6 h. Thin sections were mounted on grids and exam-
ined under the electron microscope (Philips EM410).
Autophagic Flux Analysis—Autophagy flux was analyzed by
flow cytometry and confocal microscopy using DQTMRed BSA
(self-quenched red BODIPY dye conjugated to BSA;Molecular
Probes, Eugene, OR). Red DQ-BSA requires enzymatic cleav-
age in acidic intracellular lysosomal compartments to generate
a highly fluorescent product that can be monitored by confocal
microscopy or flow cytometry. GFP-LC3 transiently express-
ing-RAW264.7 cells were incubated in RPMImedia containing
DQ-BSA (10 g/ml) for 30 min and washed twice with PBS.
Cells were then treated with LeTx in the presence or absence of
CA074-Me for 60 min and fixed with 4% formaldehyde. Colo-
calization of GFP-LC3 and red fluorescent of DQ-BSA were
imaged using a Bio-Rad Radiance 2000 two-photon confocal
microscope and LaserSharp 2000 software. For flow cytometry
analysis, the human monocytic cell line THP-1 was incubated
in RPMI media containing DQ-BSA (10 g/ml) for 15 min at
37 °C in 5% CO2. Cells were washed twice with PBS and then
incubated for 45 min to ensure that DQ-BSA had reached the
lysosomal compartment. THP-1 cells were further incubated in
the presence or absence of CA074-Me for the indicated times.
Cells were harvested, and red-fluorescent of DQ-BSA was ana-
lyzed by flow cytometry using a FACSCalibur flow cytometer
(BD Biosciences) and CellQuest (BD Biosciences) and FlowJo
(Treestar) software. For confocal images analysis, cells were
plated on coverslips after treatment as above and fixed with
4% formaldehyde. The fluorescent degradation products of
DQ-BSA in lysosomes were imaged using a Bio-Rad Radi-
ance 2000 two-photon confocal microscope and LaserSharp
2000 software.
RESULTS
CathepsinB InhibitorCA-074-Me Inhibits LeTx-inducedCell
Death of Macrophages—We examined whether CTSB is
involved in LeTx-induced cell death using the CTSB-specific
chemical inhibitor CA074-Me (CA074). RAW264.7 macro-
phages, which express NALP1b, were rapidly killed by LeTx,
and CA074, but not other cathepsin inhibitors targeting
cathepsin G (CTSGi) and cathepsin K (CTSKi), significantly
prevented cell death (Fig. 1A). The cell death protective effect of
FIGURE 1. The cathepsin B inhibitor CA074 prevents cell death induced by
anthrax lethal toxin in RAW 264.7 macrophages. A, RAW264.7 murine
macrophages were treated with different kinds of cathepsin inhibitors
(cathepsin G inhibitor (CTSGi; 100 M), cathepsin K inhibitor (CTSKi;100 M),
cathepsin B inhibitor (CA074-Me; 100 M), and proteasome inhibitor (MG132;
10 M) for 1 h and then treated with LeTx (250 ng/ml LF and 500 ng/ml PA) in
the presence of the inhibitors for 5 h. MTT was added 2 h before the end of the
experiment for cell death determination. Data are expressed as the mean 
S.D. (n  3). B, RAW264.7 cells were pretreated with different concentrations
of CA074-Me and then treated with LeTx (250 ng/ml LF and 500 ng/ml PA) for
5 h. Cell death assays were performed as above in A. Data are expressed as the
mean  S.D. (n  4).
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CA074 was dose-dependent (Fig. 1B) and more pronounced in
early cell death and at low LeTx doses (supplemental Fig. 1, A
and B). As previously shown (31), the proteasome inhibitor
MG132 prevented LeTx-induced cytolysis to similar extents of
100 M CA074 (Fig. 1A).
CathepsinB Inhibitor Inhibits theDelivery of LF into theCyto-
plasm from Late Endosomes—We further examined whether
CA074 inhibited LeTx-induced cell death before or after the
release of LF into the cytoplasm and whether the protective
effect was specific to cathepsin B. Based on MEK1 N-terminal
cleavage, which indicates the release of LF into the cytoplasm,
CA074 appeared to inhibit the cytoplasmic delivery of LF (Fig.
2A). In comparison, the proteasome inhibitor MG132 pre-
vented LeTx-induced cell death to a similar extent as CA074
(Fig. 1A) but had no effects onMEK1 cleavage by LF (Fig. 2A) as
previous reported (31). MEK1 cleavage by LF was also greatly
suppressed in primary bonemarrow-derivedmacrophages pre-
pared from CTSB-deficient mice (CTSB/) (Fig. 2B), indicat-
ing that CTSB, but not cathepsin L,
which could have been inhibited by
CA074 (32), was mainly responsible
for the delivery of LF into the
cytoplasm.
Delivery of LF into the cytoplasm
involves the formation of the hep-
tameric PA63 pore, which becomes
an SDS-resistant complex in acidi-
fied endosomes (28). The SDS-re-
sistant PA63 complex is then trans-
ported to lysosomes for rapid
degradation (16, 33). Thus, we
examined whether CTSB was in-
volved in intracellular uptake of
LeTx by analyzing formation of
the SDS-resistant PA63 complex.
CA074 had no effect on SDS-resist-
ant PA63-heptamer formation but,
rather, protected it from lysosomal
degradation (Fig. 2C, upper panel).
The total amounts of intracellular
LF did not change by CA074 (Fig.
2C, lower panel), indicating that
CA074 did not interfere intracellu-
lar uptake of LeTx. It has also been
suggested that internalized LeTx is
sequentially transported to early
endosomes, intralumenal vesicles
(also known as multivesicular bod-
ies), and late endosomes before
being released into cytoplasm
through back fusion with the limit-
ing membrane (17, 18). We further
examined in which endosomal
pathways LF delivery was inhibited
byCA074. Early and late endosomes
were isolated from LeTx-treated
RAW264.7 cells in the presence or
absence of CA074. The SDS-resis
tant PA63 heptamer and LF were highly enriched in late endo-
somes, which co-fractionated with the late endosomal small
GTPase rab7 (34, 35) and CTSB in the presence of CA074 (Fig.
2D, right panel). Unlike PA, overall amounts of LF did not
change (Fig. 2C, lower panel), and LF was mostly released
into the cytoplasm in the absence of CA074 but retained in
late endosomes in the presence of CA074 (Fig. 2D). Similar
experiments were repeated in primary bone marrow-derived
macrophages prepared from wild type (CTSB/) and
CTSB/ mice. Unlike CA074-treated cells, CTSB/ cells
had no significant changes in total amounts of PA63 heptam-
ers (Fig. 2E, upper panel), suggesting that PA was degraded
mainly by a CTSB-independent but CA074-sensitive prote-
ase such as cathepsin L. However, consistent with data
shown in Fig. 2B, more LF was retained in endosomes, and
less was released into the cytoplasm of CTSB/ than
CTSB/ cells (Fig. 2E, lower panel). These observations
suggest that LF is transported to late endosomes and
FIGURE 2. Inhibition of cathepsin B blocks MEK1 cleavage induced by anthrax lethal toxin through delay-
ing LeTx release into the cytoplasm. A, RAW264.7 cells were pretreated with CA074-Me (100 M) or MG132
(10 M) for 1 h and treated with LeTx (250 ng/ml LF and 500 ng/ml PA) for 2 h. MEK1 cleavage was analyzed by
Western blots. Immunoblotting for p38 was used as a loading control. NT, N terminus. B, bone marrow-derived
macrophages from C57BL/6 (Ctsb/) or (Ctsb/) mice were treated with LeTx (250 ng/ml LF and 500 ng/ml
PA) for the indicated times, and MEK1 cleavage was analyzed by Western blots. The immunoblot for p38 was
used as a loading control. C, C57 bone marrow-derived immortalized macrophage cells were incubated in the
presence or absence of CA074-Me (100 M) for 1 h and treated with LeTx (250 ng/ml LF and 500 ng/ml PA) for
1 h. LeTx-treated cells were washed twice with PBS and incubated for another 1 h or 2 h with fresh media. Cell
homogenates were heated at 96 °C for 5 min and separated using SDS-PAGE. PA-heptamer stability was ana-
lyzed by immunoblot. D, RAW264.7 macrophages were pretreated with CA074-Me (100 M) for 1 h and treated
with LeTx (250 ng/ml LF and 500 ng/ml PA) for 1 h. Macrophages were washed twice with PBS and harvested
after another 1 h of incubation at 37°C. Macrophage homogenates were prepared in 1 extraction buffer as
described under “Experimental Procedures,” and the gradient was centrifuged for 10 h at 35,000 rpm in the
SW41 rotor (Beckman). Gradient fractions were collected and analyzed by Western blots. E, bone marrow-
derived macrophages from C57BL/6 (Ctsb/) or (Ctsb/) mice were treated with LeTx (250 ng/ml LF and 500
ng/ml PA) for 90 min, and macrophages were washed twice with PBS. Half of the cells were harvested, and
intracellular total endosomal compartments were prepared as under “Experimental Procedures.” The remain-
ing cells were further incubated at 37°C for 90 min, and intracellular total endosomal compartments were
prepared as above. PA-heptamer stabilities were analyzed by immunoblots (top panel). Bone marrow-derived
macrophages from C57BL/6 (Ctsb/) or (Ctsb/) mice were treated with LeTx (250 ng/ml LF and 500 ng/ml
PA) for 90 min. The cytosolic and endosomal compartments were prepared as above, and LF was analyzed by
Western blot. Immunoblots for Rab7 and p38 were used as loading controls (bottom panel).
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released into the cytoplasm mainly through a CTSB-sensi-
tive pathway.
Lysosomal Fusion with Late Endosomes Is Required for the
Delivery of LF into theCytoplasm—BecauseCTSB is likely com-
partmentalized in lysosomes, we examined whether lysosomal
fusion with LeTx-containing vesicles was required for the cyto-
solic delivery of LF. Several molecules known to be involved in
the lysosomal fusion process were examined for their involve-
ment in the cytosolic delivery of LF. The chemical lysosomal
fusion inhibitor vinblastine prevents microtubule-dependent
transport of lysosomes to endosomes (36, 37). RAW264.7 mac-
rophages pretreated with vinblastine at various doses were
more resistant to LeTx-induced cell death in a dose-dependent
manner (Fig. 3A). MEK1 cleavage by LeTx was also inhibited
(Fig. 3A, lower panel), suggesting that LF was not released into
the cytoplasm. The LAMP1 and -2 play an important role in the
fusion of lysosomes with other vacuoles, likely through a
dynein-mediated transport of lysosomes and phagolysosome
formation, and cells deficient in LAMP1 and LAMP2 showed
defects in lysosomal fusion with autophagic vacuoles and pha-
gosomes (38, 39). Within 90 min of
LeTx treatment, wild type immor-
talized MEFs incorporated LF into
the cytoplasm, and subsequently,
MEK1 was cleaved by LF, whereas
MEFs lacking LAMP1 and -2
requiredmore time (150min) and
higher doses to reach similar
extents of MEK1 cleavage (Fig. 3B).
The fusion of late endosomes and
lysosomes requires the presence of
N-ethylmaleimide-sensitive factor
(NSF), soluble NSF attachment pro-
teins, and a small GTPase of
the Rab family such as Rab7
(40). After formation of tethering
between late endosomes and lyso-
somes, a trans-solubleN-ethylmale-
imide-sensitive factor attachment
protein receptor (SNARE) complex
must be formed to fuse the mem-
branes (41). One of the key mole-
cules required for heterotypic late
endosome-lysosome fusions is
VAMP7, also known as tetanus-
neurotoxin-insensitive VAMP or
synptobrevin-like-1 (42). We used
easily transfected HEK293 cells to
specifically knock down VAMP7
mRNA using siRNAs and examined
MEK1 cleavage induced by LeTx.
About 50%ofVAMP7atmRNA lev-
els were diminished by the siRNAs,
based on a real-time reverse tran-
scription-PCR analysis (data not
shown), andWestern blots also sup-
ported the knockdown of VAMP7
by the siRNAs (Fig. 3C, left panel).
Indeed, knocking down VAMP7 partially prevented LeTx-in-
duced MEK1 cleavage, and intact MEK1 was readily detectible
byWestern blots, albeit the level of intactMEK1was lower than
that of nontreated cells (Fig. 3C, right panel). To further address
whetherCTSB activity is required for the process of, or after the
fusion between late endosomes and lysosomes, we examined
co-localization of CTSB with PA or LF in the presence or
absence of CA074 using confocal microscopy. Immunofluores-
cent staining in HEK293 cells with CTSB and PA or LF indi-
cated that both PA and LF were co-localized with CTSB-con-
taining vesicles, and the colocalization was more prominent in
cells treated with CA074 (Fig. 3D), suggesting that CA074 did
not block fusion of LeTx-containing vesicles with CTSB-con-
taining lysosomes.
LeTx-induced Autophagy Facilitates the Delivery of LF into
the Cytoplasm—Recently, LeTx was shown to induce autoph-
agy, suggested to be a long term (after 24–48 h of LeTx treat-
ment) survival mechanism of LeTx-exposed human promyelo-
cytic leukemia HL-60 cells (43). We also observed the
formation of autophagy-related structures, likely sequestered
FIGURE 3. Late endosome and lysosome fusion is required for release of LeTx into the cytoplasm.
A, inhibition of microtubule activity blocked cell death and MEK1 degradation induced by LeTx. RAW264.7
macrophages were incubated in the absence or presence of the microtubule inhibitor vinblastine (0 –250
ng/ml) for 1 h and treated with LeTx (125 ng/ml LF and 250 ng/ml PA) for 5 h. Cell death was measured using a
MTT assay (top panel). Data are expressed as the mean  S.D. (n  3). RAW264.7 macrophages were pretreated
with the vinblastine (250 ng/ml) for 1 h and treated with LeTx (125 ng/ml LF and 250 ng/ml PA) for 2 h. MEK1
degradation was analyzed by Western blots (bottom panel). NT, N terminus. B, Lamp1/2 deficiency in MEF cell
lines caused delayed MEK1 degradation induced by LeTx. Mouse embryo fibroblast wild type (Lamp1/2/) or
Lamp1/2 double-deficient (Lamp1/2/) cell lines were treated with different doses of LeTx for 2 h, and MEK1
degradation were analyzed by immunoblotting (top panel). Lamp1/2/ or Lamp1/2/ MEF cell lines were
treated with LeTx (250 ng/ml LF and 500 ng/ml PA) for the indicated times, and MEK1 degradation was ana-
lyzed by Western blot (bottom panel). C, HEK293 cells were transfected with siRNA against VAMP7 or control
siRNA. A portion of the transfected cells was harvested at 42 h post-transfection for confirmation of protein
knockdown, and the remaining cells were treated with LeTx (250 ng/ml LF and 500 ng/ml PA) for 2 h. MEK1
degradation was analyzed by Western blot. D, inhibition of cathepsin B activity caused enhanced colocal-
ization with cathepsin B-containing vesicles and PA or LF. HEK293 cells were pretreated with or without
CA074-Me (100 M) for 1 h and then treated with LeTx (250 ng/ml LF and 500 ng/ml PA) for 1 h. Cells were
washed twice with media and further incubated at 37°C for 1 h. After blocking with 10% goat serum, cells
were immunostained with anti-CTSB, anti-PA or anti-LF antibodies, and visualized using a confocal micro-
scope; scale bar, 5 m.
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mitochondria or other organelles, in LeTx-treated RAW264.7
cells using electron microscopy (Fig. 4A). During autophagy, a
ubiquitin-like microtubule-associated protein 1 light chain 3-I
(LC3-I, the mammalian orthologue of yeast autophagy-related
gene (Atg8; 18 kDa), converts to a phosphatidylethanolamine-
conjugated LC3-II (16 kDa) form, and the amount of LC3-II
correlates with the extent of autophagosome formation (44).
Thus, we examined the amounts of LC3-II to examine whether
autophagy was induced by PA or protease activity of LF. In fact,
the amounts of LC3-II formation by PA alone or PA with pro-
tease-inactivated mutant LF were similar as those induced by
LeTx (Fig. 4B). The amounts of LC3-II were even further
enhanced when cells were pretreated with CA074 or vinblas-
tine (Fig. 4C). When we visualized cells using immunofluores-
cent staining against PA or LF and transiently expressed GFP-
LC3 followed by confocal microscopy, both PA (80–90% of PA
puncta) and LF (40–50% of LF puncta) were co-localized with
LC3-II containing autophagosomes or amphisomes (Fig. 4D),
suggesting that the delivery of LF into the cytoplasmwas at least
in part carried out through autophagy processes.
To evaluate the role of autophagy in the delivery of LF into
the cytoplasm, we examined whether inhibition or enhance-
ment of autophagy processes affects
the rate of LF delivery into the cyto-
plasm. In these experiments we
used the human monocytic cell line
THP-1 cells, which had slower rates
of LeTx uptake and higher sensitiv-
ity to the autophagy inhibitor
3-methyladenine (3-MA). During
serum starvation conditions, the
rates of MEK1 cleavage and LC3-II
formation were much faster than
those of cells in normal serum con-
ditions (Fig. 4E). In line with these
data, 3-MA inhibited LeTx-induced
MEK1 cleavage andLC3-II accumu-
lation. Basal levels of phospho-
ERK1 and -2, of which phosphoryla-
tions aremainlymediated byMEKs,
were also diminished by LeTx, and
3-MA was able to restore the basal
levels of the phosphorylations (Fig.
4F). The degradation of PA63 hep-
tamer was also suppressed by 3-MA
(Fig. 4F, top panel). Altogether,
these data support that autophagy
induced by PA facilitated the deliv-
ery of LF into the cytoplasm.
Cathepsin B Activity Is Required
for Autophagic Flux—Because pre-
vious results suggested that autoph-
agy was required for an efficient
delivery of LF into the cytoplasm
but CA074 enhanced LC3-II forma-
tion, we investigated whether CTSB
was involved in the process of auto-
phagy and, if so, in which step of
autophagy process using DQTM Red BSA (DQ-BSA). DQ-BSA
is a derivative of bovine serum albumin that is labeled with a
self-quenched red fluorescent dye and dequenched by lyso
somal proteases, releasing red fluorescence. As shown in Fig.
5A, left panels, red fluorescent dequenched DQ-BSA-contain-
ing vesicles were partly co-localized with LC3-positive puncta
after LeTx treatments. CA074, even at high concentrations
(100 M), had no effect on the co-localization of dequenched
DQ-BSA vesicles with LC3-positive puncta (Fig. 5A, right pan-
els), suggesting that CA074 had no effects on the fusion process
of endosomes and lysosomes but, rather, enhanced or stabilized
the fusion of dequenched DQ-BSA-containing vesicles
(endolysosomes) and LC3-containing puncta (autophago-
somes). Thus, we examined whether CTSB deficiency or
CA074 could prevent autophagy flux. DQ-BSA was pre-loaded
and dequenched in THP-1 cells, and the rate of disappearance
of dequenchedDQ-BSAwasmonitored. DequenchedDQ-BSA
disappeared over the time period of 21 h (Fig. 5B). However, in
the presence of CA074 (50 M), the flux of dequenched DQ-
BSAwas significantly delayed (Fig. 5B and supplemental Fig. 2).
Also, cells treated with CA074 (50 M) or CTSB-deficient mac-
rophages (CTSB/) showed enlarged dequenched DQ-BSA-
FIGURE 4. Induction of autophagy is required for effective trafficking of LeTx. A, LeTx induced the forma-
tion of intracellular vacuoles in macrophages. RAW264.7 macrophages were incubated in absence or presence
of LeTx (250 ng/ml LF and 500 ng/ml PA) at 37 °C for 1 h and washed twice with ice-cold PBS. Cells were then
fixed with 2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer, and grids with specimen were prepared as
described under “Experimental Procedures.” Micrographs were taken with a transmission electron micro-
scope. Scale bars show 2 m in length for the lower magnification and 0.2 m for higher magnification. B, LeTx
induced LC3-II formation in a PA-dependent manner. RAW264.7 macrophages were treated with PA and LF
(PA  LF, 500 ng/ml PA and 250 ng/ml LF), PA and inactive LF (PA  mLF, 500 ng/ml PA and 250 ng/ml LF), PA only
(500 ng/ml PA), or LF only (250 ng/ml PA) for 2 h. Induction of autophagy was analyzed by immunoblotting
against LC3-II. An immunoblot for p38 MAPK was used as a loading control. C, RAW264.7 cells were pretreated
with CA074-Me (50 or 100 M) or the microtubule inhibitor vinblastine (0.25 M) and treated with LeTx (125
ng/ml LF and 250 ng/ml PA) for 2 h. LC3-II accumulation was analyzed by Western blots. D, N-terminal GFP-
conjugated LC3 was transiently transfected in RAW264.7 macrophages and treated with LeTx (250 ng/ml LF
and 500 ng/ml PA) for 1 h at 16 h post-transfection. Cell were washed twice with normal media and further
incubated at 37°C for 30 min. Cells were then fixed and immunostained with anti-PA or anti-LF as described
under “Experimental Procedures.” GFP-conjugated LC3 and PA (top panel) or LF (bottom panel) were visualized
using a Zeiss LSM510 META confocal microscope; scale bar, 5 m. E, THP-1 cells were incubated with serum or
without serum for 4 h and treated with LeTx (125 ng/ml LF and 250 ng/ml PA) for the indicated times. MEK1
degradation or LC3-II formation was analyzed by Western blots. Immunoblot for actin was used as a loading
control. NT, N terminus. F, THP-1 cells were treated with different doses of 3-MA for 1 h and exposed by LeTx for
2 h. PA-heptamer and MEK1 degradation, phospho-ERK (pERK), and LC3-II formation were analyzed by Western
blots.
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containing vesicles (Fig. 5C, top and bottom panels). These
results consistently suggested that CTSB was required for
clearing dequenched DQ-BSA or flux of amphisomes.
ANTXR2-mediated LeTx Uptake Requires Autophagic Flux
for the Cytoplasmic Delivery of LF—PA binds to one of the two
ANTXRs: ANTXR1 and ANTXR2 (45). Because the delivery of
LF into the cytoplasm was not completely inhibited by CA074,
we investigated whether the involvement of CTSB was recep-
tor-specific. ANTXR1 or -2 was specifically knocked down up
to 70% at the mRNA level in HEK293 (Fig. 6A, left panel) and
THP-1 cells (data not shown) by siRNAs. In ANTXR1-knock-
down cells, CA074 almost completely inhibitedMEK1 cleavage
by LeTx, whereas in ANTXR2-knockdown cells MEK1 cleav-
age was not significantly inhibited (Fig. 6B). Similarly, basal
levels of phosphorylated ERK1 and -2 were correlated with
intact MEK1 levels. LC3-II formation by LeTx was induced to
similar extents in these cells, and the levels of LC3-II were fur-
ther enhanced in the presence of CA074 as previously observed
in RAW264.7 cells (Fig. 4C). To further corroborate that
ANTXR2 utilized a CA074-sensitive or CTSB-mediated proc-
ess, we investigated the effect of CA074 on LeTx uptake in
ANTXR1- and -2-deficient CHO-K1 cells (R1/R2) reconsti-
tuted with full-length ANTXR1-sv1 (R1/R2) or ANTXR2489
(R1/R2) (46). Consistent with the data shown in Fig. 6A,
CA074 failed to inhibit MEK1 cleavage induced by LeTx in
R1/R2 cells, whereas MEK1 cleavage by LeTx was com-
pletely inhibited in R1/R2 cells (Fig. 6B). The amounts of
LC3-II were also increased in both R1/R2 and R1/R2 cells
by LeTx, whichwas further increased in the presence of CA074.
We also examinedwhetherANTXR2-mediated LFdeliverywas
mediated through autophagy. The autophagy inhibitor, 3-MA,
which at least partially prevented LC3-II formation by LeTx in
either ANTHR1 or ANTXR2 knockdown cells, was able to pre-
ventMEK1 cleavage in ANTXR1 but not ANTXR2 knockdown
cells (Fig. 6C). These results collectively suggest that ANTXR2
but not ANTXR1 delivery of LF into the cytoplasm was medi-
ated through a CTSB- and autophagy-dependent pathway.
DISCUSSION
This study showed that CTSB is involved in the delivery of
ANTXR2-associated LF into the cytoplasm. It appeared that
CTSB played an important role in autophagic flux whereby LF
was delivered from intralumenal vesicles into the cytoplasm
likely through back fusion. The current model of LeTx entry
into the cytoplasm involves translocation of LF from the lumi-
nal compartment of themultivesicular late endosomes through
FIGURE 5. Cathepsin B inhibition causes defective autophagy flux. A, RAW264.7 cells were electroporated with GFP-LC3 plasmid and incubated in DMEM
containing DQ-BSA (10 g/ml) for 30 min. Cell were then washed twice with DMEM and treated with LeTx (250 ng/ml LF and 500 ng/ml PA) for 60 min in the
presence or absence of CA074-Me (100 M). Cells were fixed, and colocalization of GFP-LC3 and red fluorescent of DQ-BSA was imaged using a Bio-Rad
Radiance 2000 two-photon confocal microscope and LaserSharp 2000 software. Arrows show the colocalization of dequenched DQ-BSA vesicles with LC3-
positive puncta; scale bar, 5 m. B, THP-1 cells were incubated in RPMI media containing DQ-BSA (10 g/ml) for 15 min at 37 °C in 5% CO2. Cells were washed
and incubated further in regular growth media for 45 min to ensure that DQ-BSA had reached the lysosomal compartment. Cells were then further incubated
in regular growth media in the presence or absence of CA074-Me (50 M), then harvested at indicated time points. Cells were analyzed using flow cytometry.
C, for confocal images analysis, THP-1 cells were plated on coverslips after treatment as above in B, and cells were incubated in RPMI media with or without
CA074-Me (50 M). Cells were then fixed with 4% formaldehyde at the indicated time point. The fluorescent products of DQ-BSA were imaged using the Bio-Rad
Radiance 2000 two-photon confocal microscope and LaserSharp 2000 software. Dotted lines indicate the cell margin; scale bar, 5 m. D, C57 wild type (CTSB/)
or cathepsin B-deficient (CTSB/) cell lines were plated on coverslips and incubated in RPMI media containing DQ-BSA (10 g/ml) for 15 min at 37 °C in 5%
CO2. Cells were washed twice with PBS and incubated in RPMI media for the indicated times. Cells were fixed as above in C, and the fluorescent degradation
products of the DQ-BSA in lysosome were imaged using Bio-Rad Radiance 2000 two-photon confocal microscope and LaserSharp 2000 software. Dotted lines
indicate the cell margin.
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an undefined back-fusion process with the limiting membrane
(17, 47). This study showed that LF accumulated in late endo-
somes in the presence of CA074 (Fig. 2D) or in CTSB-deficient
macrophages (Fig. 2E), and CTSB-containing lysosomes colo-
calized with LF-containing endosomes (Fig. 3D), suggesting
that CTSB activity was required for the delivery of LF from
endolysosomes into the cytoplasm. These data are somewhat
unexpected, considering that lysosomal proteases can cause
early degradation of LF. However, it was postulated that LFs are
packaged into endosomal carrier vesicles, and unlike PA, which
is exposed to lysosomal proteases and undergoes a rapid degra-
dation, LF is sheltered in the lumen of endosomal carrier vesi-
cles and protected from degradation (48). There are several
evidences that late endosomes and lysosomes fuse to form
hybrid organelles, which then undergo back fusion (40, 49, 50).
Therefore, we speculate that lysosomal fusion is a cue for back
fusion of intralumenal vesicles, which can be a safety measure
to ensure that endocytosed molecules or phagocytosed parti-
cles are degraded by lysosomal proteases before back fusion
starts.
This study also showed that the CTSB-mediated delivery of
LF into the cytoplasmwas involved only for the ANTXR2 path-
way. Although ANTXR1 and -2
share high amino acid sequence
homology (60% in extracellular
domains and 68% in the first 145
residues of cytoplasmic domain)
and post-translational modifica-
tions such as palmitoylation and
ubiquitination (10, 11), the pH
thresholds for PA63 heptamers to
form a transmembrane pore are dif-
ferent in these two receptors (14,
51). It was shown that PA dissoci-
ates from ANTXR2 and forms a
pore at a lower pH than that
required for ANTXR1. The lower
pH requirement of ANTXR2 is in
line with our observations that the
cytoplasmic delivery of LF through
ANTXR1 could have occurred in
early endosomes and, therefore, was
insensitive to CA074 (Fig. 6). How-
ever, PA dissociated from ANTXR2
only in mature endosomes with
lower pH, resulting in the release of
LF into the lumen of intralumenal
vesicles followed by CA074-sensi-
tive back fusion with the limiting
membrane and release of LF into
the cytoplasm (Fig. 7).
Autophagy is a dynamic, multi-
step lysosomal degradation pathway
initiated by forming a double-mem-
brane sac called the isolation mem-
brane, which elongates until two
leading edges meet to form double
membrane-bound structures called
the autophagosomes. The outer membrane of autophago-
some fuses with endosomes or lysosomes to form an amphi-
some or autolysosome. It is a cell survival and protective
mechanism, particularly during starvation or infections,
achieved by procuring energy sources through intracellular
organelle turnover (52) or by killing phagocytosed microbes
(53, 54). At the same time autophagy can also be utilized by
microbes for their survival and evasion of host cell-protec-
tive mechanisms (55). This study, consistent with the previ-
ous report of Tan et al. (43), showed that PA alone could
induce autophagy (Fig. 4, A and B) through either ANTXR1
or -2 (Fig. 6). How ANTXRs triggered autophagy is still to be
investigated, but because PA can induce tyrosine phosphor-
ylations of the ANTXR-co-receptor lipoprotein-receptor-
related protein 6 (LRP-6) (13), it is possible that the phos-
phorylation of LRP-6 or possibly other ANTXR-associated
proteins triggered autophagy formation. We further showed
that ANTXR2-associated LFs took advantage of the host
autophagic flux process to reach the cytoplasm (Figs. 4,D–F,
and 6B). Both early and late endosomes fuse with autophagic
vacuoles (56), which is even necessary for the formation of
amphisomes or autolysosomes and subsequent autophagic
FIGURE 6. Cathepsin B is involved in ANTXR2-dependent LeTx delivery through autophagic flux.
A, HEK293 cells were transfected with control siRNA (si-Scramble) or human (h) ANTXR1- or ANTXR2-specific
siRNAs (si-ANTXR1 or si-ANTXR2), and at 42 h post-transfection, portions of the cells were harvested for reverse
transcription-PCR (left panel). The remaining cells were incubated in the presence or absence of CA074-Me (100
M), and treated with LeTx (250 ng/ml LF and 500 ng/ml PA) for 2 h. MEK1 degradation, down-regulation of
phospho-ERK (pERK), and LC3-II formation were analyzed by Western blots (middle panel) and MEK1-NT immu-
noreactivities were analyzed using the NIH-Image program. Data are expressed as mean  S.D. (n  3; *,
significant, p 	 0.05; NS, not significant with p  0.5). NT, N terminus. B, ANTXR1/R2-deficient CHO cells
(R1/R2), ANTXR1-reconstituted CHO cells (R1/R2), or ANTXR2-reconstituted CHO cells (R1/R2) were
treated with LeTx (500 ng/ml LF and 1000 ng/ml PA) for the indicated times. MEK1 degradation and LC3-II
formation were analyzed by Western blot. Immunoblots for HA or actin were used for transfection or loading
control. C, human monocytic THP-1 cells were transfected with control siRNA or siANTXRs, and after 42 h cells
were treated with LeTx as above. MEK1 degradation and LC3-II formation were analyzed by Western blot (upper
panel), and LC3-II immunoreactivities were analyzed using NHI-Image program (lower panel). Data are
expressed as the mean  S.D. (n  2).
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flux (57). Therefore, the release of LF through autophagic
flux is not a surprising proposition.
We also showed that CTSB was required for efficient auto-
phagic flux but not in the fusion processes of autophagosomes
and lysosomes, based on the facts that there were no defects in
the dequenching process of DQ-BSA in CA074-treated cells
(Fig. 5A) and in CTSB-deficient cells (data not shown) and on
enhanced colocalization of PAorLFwithCTSB (Fig. 3D) aswell
as dequenched DQ-BSA-containing puncta (Fig. 5A) in the
presence of CA074 (Figs. 3D and 5A). However, CA074-treated
or CTSB-deficient cells showed more LC3-II accumulation
than nontreated (Figs. 4C and 6) or wild type cells (data not
shown), respectively, and clearing cleaved DQ-BSA in autoly-
sosomes was delayed by CA074 treatment (Fig. 5, B and C) and
in CTSB/ cells (Fig. 5C, bottom panel). These results suggest
that CTSB is involved in the flux of autophagy or amphisomes.
Although little is known about the mechanism of autophago-
some intralumenal vesicle back fusion, defects in autophagy
fluxwere suggested to be involved in the cytoplasmic delivery of
LF. The Niemann Pick Type C disease (NPC) is an autosomal
recessive neurodegenerative disease due to mutations inNPC1
or NPC2 genes involved in intracellular cholesterol transport
(58). NPC1 cells or cells treated with the drug U18666A, which
causes a phenotype identical to NPC1 mutations (59), were
shown to have defects in back fusion of intralumenal vesicles
and release of LF into the cytoplasm, likely caused by accumu-
lations of cholesterol and, possibly, protein contents in late
endosomes (17). Also, Npc1-deficient mice showed significant
higher levels of LC3-II and the presence of autophagic vacuole-
like structures and multivesicles in brain tissue (60). These
studies suggest that alteration of lipid composition and possibly
protein contents in late endosomes or autophagic vacuoles
could affect intralumenal vesicle back fusion. However, how
lysosomal proteases such as CTSB or lipases affect this back
fusion still remains to be addressed.
While this manuscript was in preparation, Newman et al.
(61) reported that CA074 protected from LeTx-induced cyto-
toxicity in macrophages. The protection by CA074 was sug-
gested to be mediated by broader inhibitory effects of CA074
and after the release of LF into the cytoplasm. The study also
detected a delay in the cleavage of MEKs by CA074; however,
the delay was not as prominent as we observed in this study.
Because their study used very high doses of LeTx (1g/ml PA
and LF) and CA074 (500 M), most of LF released into the
cytoplasm was likely mediated by ANTXR1. At lower doses of
CA074 (	100M) and LeTx (	500 ng/ml), robust inhibition of
LeTx-induced MEK1 cleavage and cytotoxicity were detected
inCA074-treated andCTSB/ cells (Figs. 1 and 2, supplemen-
tal Fig. 1).
Physiologically speaking, althoughANTXR1 and -2 are ubiq-
uitously expressed in human tissues (9), ANTXR2 has been
shown to play a more important role in both anthrax spore-
induced macrophage death (62) and LeTx-induced animal
lethality (63, 64). ANTXR1, however, is prevalently expressed
in cancer cells (65–67), particularly up-regulated in human
colorectal cancer endothelium (68), suggesting it as a potential
tumor target. Therefore, targeting CTSB or autophagy could be
a useful therapeutic strategy for reducing the toxic effects of
LeTx without affecting its anti-tumor activity.
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